Kliniska studier vid Tema Cancer

PRORECT. Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT):A Prospective Randomized Swedish Phase II Trial

Alexander Valdman

CIM-HIPEC. The native immune system and the development of carcinomatosis among patients with colorectal cance

Caroline Nordenvall

CIM-IBD. Single-cell analysis of intestinal lymphocytes reveals targets for treatment of inflammatory bowel disease

Caroline Nordenvall

CITCCA pilot. CIrculating Tumour DNA in Colorectal CAncer, pilotstudie

Anna Martling

CRUISE. Restorative treatment with ileorectal anastomosis or ileal pouch anal anastomosis in patients with ulcerative colitis

Caroline Nordenvall

EFFIPEC. EFFIPEC – Efficacy of Hyperthermic Intraperitoneal ChemotherapySingle-arm Phase I study, followed by an open-label, randomized, controlled registry-based phase III trial

Gabriella Palmer

PelvEx II. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer

Henrik Iversen

SCAR-studien. Operation eller behandling med koloskop efter borttagande av tidig tarmcancer (SCAR-studien)

Richard Marsk

TRIOCOL. TRIOCOL - the study of third-line advanced drug treatment vs colectomy in patients with ulcerative coliti

Caroline Nordenvall

SELSA. Selective defunstionen stoma approach in low anterior resection for rectal cancer(SELSA): a prospective study and a nested randomised clinical trial

Naseer Baloch

Komplikationer efter rektalcancer/carcinoskirirgi. Förekomst av komplikationer efter rektalcancer- och carcinoskirurgi samt påverkan på tarmnfunktion och livskvalitet

Mirna Abraham Nordling

RACC. The RACC trial -Robot Assisted Approach to Cervical Cancer

Henrik Falconer

SCAN-Mi-studien-cervix. Mikrobiomets associerade biomarkörers betydelse för utveckling och prognos av livmoderhals- och huvudhals-cancer.

Henrik Falconer

TITANIUM. GestaTIonal TrophoblAstic NeoplasIa assessMent

Ulrika Joneborg

GeMore-studien. Genetisk och molekylär kartläggning samt riktad behandling inom gynekologisk cancer

Josefin Fernebro

ISGA-studien (pre-GAT01). studier av immunsystemet hos patienter med gyncancer

Emelie Wallin

ct-DNA-studien på cervixcancer. Analys av cell-fritt tumör-DNA i blod.

Kristina Hellman

PARP-PET. [11C]AZ14193391 - PET as a selection tool for treatment with PARP inhibitors in patients with metastatic solid tumors

Josefin Fernebro

FOLERO. Frailty, quality Of Life and Early Reversal of temporary defunctioning Stoma in Ovarian Cancer

Sahar Salehi

GROINSS VIII. GROningen INternational Study on Sentinel node in Vulvar Cancer III, a prospective phase II treatment trial

Christina Hellman

DESTINY-Ovarian01 (DS8201-772). A Phase 3, Open-label, Multicenter, Randomized Trialof Trastuzumab Deruxtecan with Bevacizumab VersusBevacizumab Monotherapy as First-line MaintenanceTherapy in HER2-Expressing Ovarian Cancer

Hanna Dahlstrand

DESTINY-Endometrial01 (DS8201-772)- D781DC00001. DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded,Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab asFirst-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

Emelie Wallin

BNT323-01 /ENGOT-EN2. A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2-expressing recurrent endometrial cancer

Hanna Dahlstrand

DARSH-studien. Day care in Robotic Surgery Hysterectomy. Jämförande studie mellan dagvård och inneliggande vård vid robot-assisterad hysterektomi

Vilhelm Mörlin

SPCG-15. Primary radical prostatectomy versus primary radiotherapy for locally advanced prostate cancer: an open randomized clinical trial

Mats Olsson

PSMA recidiv-studien. En randomiserad jämförelse mellan konventionell "Salvage" strålbehandling och individualiserad PSMA-pet styrd behandling hos patienter med biokemiskt återfall (PSA) efter prostatacancer operation

Stefan Karlsson

ProBio . ProBio: An outcome-adaptive and randomized multi-arm biomarker driven study in patients with metastatic castrate resistant prostate cancer mCRPC)

Anders Ullén

MK3475-365. Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Enrique Castellanos

PRIS. Prostate Cancer IRE Study (PRIS) – A randomized controlled trial comparing focal to radical treatment in localized prostate cancer

Anna Lantz

METRO. Metastasis directed Stereotactic Body Radiotherapy (SBRT) for Oligo metastatic Hormone sensitive Prostate Cancer

Mattias Hedman

CAAA617A12402. Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer

Enrique Castellanos

OMAHA-004. A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA)

Anna Kristiansen

IPA. Incontinence Post robot assisted radical prostatectomy, Anatomical and functional causes

Stefan Carlsson

AMG509-Xalute. A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Chemotherapy.

Enrique Castellanos

RechARge-CA0711000. A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer(mCRPC)

Enrique Castellanos

MK2400-001-IDeate-Prostate01. A phase 3, open-label study of Ifinatamab Deruxtecan versus docetaxel in participants with metastatic castration-resistant prostate cancer (mCRPC)

Anna Kristiansen

PARIS-BIO. Prostate Androgen Response Investigation using a Stratification BIOmarker

Johan Björklund

EvoPAR02 Prostate02. A randomized, double-blind, placebo-controlled, phase 3 study of adjuvant Saruparib (AZD5305) in patients with localized high-risk prostate cancer receiving radiotherapy with androgen deprivation therapy (EvoPAR-Prostate02

Anna Kristiansen

BioBladder. Biomarker profiling to predict response and survival in patients receiving systemic therapy for advanced urothelial cancer

Anders Ullén

CA244-0012 / IZABRIGHT-BLADDER01. A Randomized, Open-Label, Phase 2/3 Trial Of Izalontamab Brengitecan Versus Platinum-Based Chemotherapy For Metastatic Urothelial Cancer In Participants With Disease Progression On Or After An Immunotherapy-Based Treatment

Anders Ullén

TINCA II - njurcancer. Det immunologiska landskapet i njurcancer

Magnus Lindskog